These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 17217313)

  • 21. Efficacy of surgery and imatinib mesylate in the treatment of advanced gastrointestinal stromal tumor: a systematic review.
    Cirocchi R; Farinella E; La Mura F; Cavaliere D; Avenia N; Verdecchia GM; Giustozzi G; Noya G; Sciannameo F
    Tumori; 2010; 96(3):392-9. PubMed ID: 20845798
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Evidence-based treatment of gastrointestinal stromal tumor (GIST) with tyrosine kinase inhibitors-imatinib and sunitinib].
    Nishida T; Omori T; Ueshima S
    Gan To Kagaku Ryoho; 2011 May; 38(5):733-7. PubMed ID: 21566432
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gene expression signatures and response to imatinib mesylate in gastrointestinal stromal tumor.
    Rink L; Skorobogatko Y; Kossenkov AV; Belinsky MG; Pajak T; Heinrich MC; Blanke CD; von Mehren M; Ochs MF; Eisenberg B; Godwin AK
    Mol Cancer Ther; 2009 Aug; 8(8):2172-82. PubMed ID: 19671739
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-effectiveness of imatinib versus interferon-alpha plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia.
    Reed SD; Anstrom KJ; Ludmer JA; Glendenning GA; Schulman KA
    Cancer; 2004 Dec; 101(11):2574-83. PubMed ID: 15493042
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Drug treatment of chronic myeloid leukemia: a cost effectiveness analysis of first- and second-line treatment ].
    Groot MT; Ossenkoppele GJ; Kramer MH; van den Boom G; Huijgens PC; Uyl-de Groot CA
    Ned Tijdschr Geneeskd; 2003 Jul; 147(30):1460-5. PubMed ID: 12908349
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-Effectiveness Analysis of Regorafenib for Gastrointestinal Stromal Tumour (GIST) in Germany.
    Tamoschus D; Draexler K; Chang J; Ngai C; Madin-Warburton M; Pitcher A
    Clin Drug Investig; 2017 Jun; 37(6):525-533. PubMed ID: 28361439
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Imatinib mesylate (glivec) as a treatment for gastrointestinal stromal tumor (GIST)--long term follow-up].
    Raccah E; Merimsky O; Kuten A; Apter S; Catane R
    Harefuah; 2007 May; 146(5):329-34, 408. PubMed ID: 17674545
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Very early detection of response to imatinib mesylate therapy of gastrointestinal stromal tumours using 18fluoro-deoxyglucose-positron emission tomography.
    Heinicke T; Wardelmann E; Sauerbruch T; Tschampa HJ; Glasmacher A; Palmedo H
    Anticancer Res; 2005; 25(6C):4591-4. PubMed ID: 16334147
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genetic changes in advanced gastrointestinal stromal tumor (GIST) patients during imatinib mesylate treatment.
    Yeh CN; Chen TW; Liu FY; Jan YY; Chen MF
    Langenbecks Arch Surg; 2006 Nov; 391(6):615-21. PubMed ID: 17024483
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gastrointestinal stromal tumor (GIST) and imatinib.
    Kubota T
    Int J Clin Oncol; 2006 Jun; 11(3):184-9. PubMed ID: 16850124
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Patterns of progression in gastrointestinal stromal tumor treated with imatinib mesylate.
    Ryu MH; Lee JL; Chang HM; Kim TW; Kang HJ; Sohn HJ; Lee JS; Kang YK
    Jpn J Clin Oncol; 2006 Jan; 36(1):17-24. PubMed ID: 16418188
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost utility of allogeneic stem cell transplantation with matched unrelated donor versus treatment with imatinib for adult patients with newly diagnosed chronic myeloid leukaemia.
    Breitscheidel L
    J Med Econ; 2008; 11(4):571-84. PubMed ID: 19450068
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [18F-FDG PET/CT in response evaluation of gastrointestinal stromal tumours treated with imatinib].
    Banzo I; Quirce R; Martínez-Rodríguez I; Jiménez-Bonilla JF; Sainz-Esteban A; Barragán J; Portilla-Quattrociocchi H; Carril JM
    Rev Esp Med Nucl; 2008; 27(3):168-75. PubMed ID: 18570858
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment interruptions and non-adherence with imatinib and associated healthcare costs: a retrospective analysis among managed care patients with chronic myelogenous leukaemia.
    Darkow T; Henk HJ; Thomas SK; Feng W; Baladi JF; Goldberg GA; Hatfield A; Cortes J
    Pharmacoeconomics; 2007; 25(6):481-96. PubMed ID: 17523753
    [TBL] [Abstract][Full Text] [Related]  

  • 35. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial.
    Joensuu H; Eriksson M; Sundby Hall K; Hartmann JT; Pink D; Schütte J; Ramadori G; Hohenberger P; Duyster J; Al-Batran SE; Schlemmer M; Bauer S; Wardelmann E; Sarlomo-Rikala M; Nilsson B; Sihto H; Monge OR; Bono P; Kallio R; Vehtari A; Leinonen M; Alvegård T; Reichardt P
    JAMA; 2012 Mar; 307(12):1265-72. PubMed ID: 22453568
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predictive factors for long-term effects of imatinib therapy in patients with inoperable/metastatic CD117(+) gastrointestinal stromal tumors (GISTs).
    Rutkowski P; Nowecki ZI; Debiec-Rychter M; Grzesiakowska U; Michej W; Woźniak A; Siedlecki JA; Limon J; vel Dobosz AJ; Kakol M; Osuch C; Ruka W
    J Cancer Res Clin Oncol; 2007 Sep; 133(9):589-97. PubMed ID: 17458563
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Imatinib for the treatment of patients with unresectable or metastatic malignant KIT-positive gastrointestinal stromal tumours: an open-label Belgian trial.
    Prenen H; Dumez H; Stefan C; Hoeben A; Wouters C; Van Lierde MA; Sciot R; van Oosterom AT; Peeters M; Polus M; Duck L; Gil T; Schöffski P
    Acta Gastroenterol Belg; 2006; 69(4):367-71. PubMed ID: 17343077
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New strategies for treating GIST when imatinib fails.
    Boyar MS; Taub RN
    Cancer Invest; 2007 Aug; 25(5):328-35. PubMed ID: 17661208
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Imatinib mesylate in the treatment of advanced gastrointestinal stromal tumors].
    Wan DS; Wu XJ; Pan ZZ; Zhou ZW; Chen G; Li LR; Lu ZH; Ding PR
    Zhonghua Yi Xue Za Zhi; 2006 Nov; 86(43):3064-7. PubMed ID: 17288838
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665.
    Eisenberg BL; Harris J; Blanke CD; Demetri GD; Heinrich MC; Watson JC; Hoffman JP; Okuno S; Kane JM; von Mehren M
    J Surg Oncol; 2009 Jan; 99(1):42-7. PubMed ID: 18942073
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.